3 Fantastic Growth Opportunities for Eli Lilly That Go Beyond GLP-1 Drugs

Eli Lilly, currently benefiting from its successful GLP-1 drugs Mounjaro and Zepbound, is strategically investing in three significant long-term growth opportunities. These include its FDA-approved Alzheimer's treatment Kisunla, which holds blockbuster potential, especially with advancements in early detection; a focus on radiopharmaceuticals for targeted cancer therapy, highlighted by its $1.4 billion acquisition of Point Biopharma and collaboration with Aktis Oncology; and a partnership with Nvidia to utilize AI for accelerating drug discovery. These initiatives are poised to unlock substantial future value and diversify the company's growth drivers.

Analysis

Eli Lilly (LLY) is strategically diversifying its growth beyond its highly successful GLP-1 drugs, Mounjaro and Zepbound, which are already generating billions in revenue. The company is actively pursuing three significant long-term opportunities expected to unlock substantial future value, aiming to sustain robust growth and mitigate reliance on a single product category. This proactive approach underpins a bullish long-term outlook for the company.

The FDA-approved Alzheimer's treatment, Kisunla, presents blockbuster potential with estimated peak sales of $5 billion annually, particularly if advancements in early detection methods, such as Mass General Brigham's sniff test, expand its addressable market. Concurrently, Eli Lilly is investing in radiopharmaceuticals for targeted cancer therapy, evidenced by its $1.4 billion acquisition of Point Biopharma and a $60 million upfront payment in collaboration with Aktis Oncology, signaling a commitment to revolutionary cancer care.

Further enhancing its innovation pipeline, Eli Lilly partnered with Nvidia to integrate artificial intelligence into drug discovery, aiming for increased efficiency, though significant benefits are anticipated closer to the decade's end. Despite a modest 7% stock increase over the last 12 months, the article maintains an extremely positive and bullish outlook on LLY's long-term prospects, suggesting it could become the first healthcare stock to reach a trillion-dollar valuation.

Key Decisions for Investors

• Investors should consider Eli Lilly (LLY) for long-term growth portfolios, given its established GLP-1 success and promising pipeline in Alzheimer's, radiopharmaceuticals, and AI-driven drug discovery.
• Monitor the progress of Kisunla's market penetration, especially as early Alzheimer's detection methods evolve, and track developments in LLY's radiopharmaceutical segment for potential breakthroughs.
• Evaluate the long-term impact of Eli Lilly's AI partnership with Nvidia, recognizing that significant returns from this initiative may materialize towards the end of the decade.